← All trials
NCT04682964
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 2, 2020
- Primary completion
- Dec 31, 2020
- Completion date
- Jun 1, 2021
- First posted
- Dec 24, 2020
- Last posted
- Dec 28, 2020
- Enrollment
- 128
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tashkent Pediatric Medical InstituteLead sponsor
- Tashkent Pediatric Medical InstituteReponsible party - principal investigator
- Tashkent Pediatric Medical InstituteStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.